He has valid concerns. You can expect the full authorization of shares issued in the end for your share price and earnings calculations. 1.7 B. A good percentage going to management.
They have delivered on the science and the presentation at ASCO is saying to me they are going to make a tissue agnostic filing for all cancers. The patent filings are showing that as well.
But management has deceived shareholders many times. Their communication with the markets is horrendous. I am not alone in this idea. There are dissatisfied longs that post here everyday.
When the share price starts winning then I will consider LP a winner. At this moment in time she has been a loser in that area. As far as I am concerned as long as the share price is a loser, I do not care even if a corporate raider came in and gave her the boot. She gets the share price up, I will start supporting her.
Market Data 
Markets 
AI
